Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Bardelli

Showing results (91-100 of 281) with videos related to

Pageof 29
Sort By:
Cell Reports. Medicine|September 11, 2024
Early-onset cancers: Biological bases and clinical implicationsGianluca Mauri, Giorgio Patelli, Andrea Sartore-Bianchi, et al.
ESMO Open|November 16, 2016
Clonal evolution and <i>KRAS</i>-<i>MET</i> coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancerAndrea Sartore-Bianchi, Emanuele Valtorta, Alessio Amatu, et al.
Cancer Research|January 16, 2013
Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesisMiriam Martini, Mariangela Russo, Simona Lamba, et al.
Cell Reports|September 10, 2014
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cellsSimona Lamba, Mariangela Russo, Chong Sun, et al.
Human Mutation|November 21, 2007
PIK3CA cancer mutations display gender and tissue specificity patternsSilvia Benvenuti, Milo Frattini, Sabrina Arena, et al.
Plos One|January 5, 2012
KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessmentNicola Normanno, Carmine Pinto, Francesca Castiglione, et al.
Clinical Colorectal Cancer|December 3, 2017
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal CancerGiovanni Germano, Gianluca Mauri, Giulia Siravegna, et al.
Plos One|May 23, 2009
Absence of AKT1 mutations in glioblastomaFonnet E Bleeker, Simona Lamba, Carlo Zanon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2011
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancersRoberta Rosa, Davide Melisi, Vincenzo Damiano, et al.
Genome Medicine|January 19, 2024
Non-canonical antigens are the largest fraction of peptides presented by MHC class I in mismatch repair deficient murine colorectal cancerGiuseppe Rospo, Rosaria Chilà, Vittoria Matafora, et al.
Pageof 29

Showing results (91-100 of 281) with videos related to

Sort By:
Pageof 29
Cell Reports. Medicine|September 11, 2024
Early-onset cancers: Biological bases and clinical implicationsGianluca Mauri, Giorgio Patelli, Andrea Sartore-Bianchi, et al.
ESMO Open|November 16, 2016
Clonal evolution and <i>KRAS</i>-<i>MET</i> coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancerAndrea Sartore-Bianchi, Emanuele Valtorta, Alessio Amatu, et al.
Cancer Research|January 16, 2013
Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesisMiriam Martini, Mariangela Russo, Simona Lamba, et al.
Cell Reports|September 10, 2014
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cellsSimona Lamba, Mariangela Russo, Chong Sun, et al.
Human Mutation|November 21, 2007
PIK3CA cancer mutations display gender and tissue specificity patternsSilvia Benvenuti, Milo Frattini, Sabrina Arena, et al.
Plos One|January 5, 2012
KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessmentNicola Normanno, Carmine Pinto, Francesca Castiglione, et al.
Clinical Colorectal Cancer|December 3, 2017
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal CancerGiovanni Germano, Gianluca Mauri, Giulia Siravegna, et al.
Plos One|May 23, 2009
Absence of AKT1 mutations in glioblastomaFonnet E Bleeker, Simona Lamba, Carlo Zanon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2011
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancersRoberta Rosa, Davide Melisi, Vincenzo Damiano, et al.
Genome Medicine|January 19, 2024
Non-canonical antigens are the largest fraction of peptides presented by MHC class I in mismatch repair deficient murine colorectal cancerGiuseppe Rospo, Rosaria Chilà, Vittoria Matafora, et al.
Pageof 29